Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02605694
Title Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

follicular lymphoma

Therapies

Duvelisib + Rituximab

Cyclophosphamide + Doxorubicin + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: adult
Covered Countries USA


No variant requirements are available.